Mutations in components of the ERK pathway are a common occurrence in human cancer. Several drugs that target components of the ERK signalling cascade such as RAF, MEK and ERK have been approved or are in late-stage clinical development, and advances are being made in developing RAS inhibitors. Here, Samatar and Poulikakos discuss the particular challenges associated with each target and provide an overview of agents in development.
- Ahmed A. Samatar
- Poulikos I. Poulikakos
